Infections with bovine viral diarrhea virus (BVDV) have a huge economic impact on cattle production and reproduction worldwide. A key factor for BVDV surveillance and eventual eradication is to efficiently detect infections and to monitor herd immunity. In this study, we generated a stable, bi-cistronic BVDV that encoded EGFP in addition to the viral proteins. Applying this recombinant virus, a new flow-cytometry-based virus neutralization test was established that enabled accurate and reliable detection of field-virus-infected and vaccinated animals. The test, which is simple and fast, is expected to support novel, effective screening procedures in eradication and vaccination programmes.
INTRODUCTION
Bovine viral diarrhea virus (BVDV) is a small (~50 nm diameter) enveloped positive-RNA virus that together with classical swine fever virus (CSFV) and border disease virus makes up the genus Pestivirus of the family Flaviviridae. The virus is spread via the faecal-oral route among cattle and related ruminants. BVDV infections are a major threat to the cattle industry, leading to annual production losses in the billion Euro range worldwide. Bovine viral diarrhoea caused by BVDV reveals a broad spectrum of manifestations that vary from asymptomatic or mild upper respiratory infections to severe acute respiratory or gastrointestinal diseases. BVDV is able to cross the placenta and infections of fetuses may lead to the birth of persistently infected (PI) animals, which constantly shed large amounts of virus and act as a reservoir of infection for other animals in the herd (Baker, 1990; . PI animals may succumb to the 100 % lethal mucosal disease when cytopathic BVDV biotypes emerge by mutation during virus replication .
The~12 kb positive-strand RNA genome of BVDV encodes a long ORF that is flanked by 59 and 39 non translated regions (NTRs) . Translation initiates at an internal ribosomal entry site (IRES) that involves RNA elements in the 59 NTR and in the 59 portion of the ORF. The translated polyprotein is cleaved by cellular and viral proteases yielding the viral structural and non-structural (NS) proteins (Lindenbach et al., 2007) . In concert with cellular factors, the NS proteins form viral replication complexes that catalyse the synthesis of progeny positive-strand viral RNAs via negative-strand RNA intermediates (Behrens & Isken, 2006) .
Studies on the BVDV RNA replication process were significantly facilitated by DNA copies (cDNAs) of the viral genome that enabled the production of infectious viral RNA by in vitro transcription (e.g., see Meyers et al., 1996; Vassilev et al., 1997; Mendez et al., 1998) . Thus, reverse-genetics studies of the BVDV 39 NTR revealed a bipartite organization of this region of the viral genome. A highly conserved region (39 C) at the immediate 39 end of the viral RNA (Deng & Brock, 1993) (Fig. 1 ) contains inalterable elements that are suggested to compose the negative-strand promoter of the initial replication complex (Yu et al., 1999) . Upstream of 39 C, i.e. downstream of the translational stop codon, the 39 NTR encloses a variable region (39 V) that displays a remarkable heterogeneity in size and nucleotide composition between different pestiviruses and virus subtypes (Becher et al., 1998; Isken et al., 2004; Pankraz et al., 2005) . Whilst some conserved RNA elements of 39 V were shown to be important for viral replication (Isken et al., 2003 (Isken et al., , 2004 , a defined region was found to be permissive for genetic changes. It was applied as an insertion site (IS) for foreign genetic elements to generate stable BVDV recombinants (Baroth et al., 2010) (Fig. 1 ).
Decades of efforts in Europe and the US support the opinion that in regions with high virus incidence, coordinated vaccination programmes combined with the elimination of PI animals and biosecurity measures are best able to 3These authors contributed equally to this work. eradicate BVDV (Moennig et al., 2005) . The implementation of such programmes as well as the fact that a high proportion of the infections are subclinical requires rapid, accurate and inexpensive tests that enable a reliable evaluation of an animal's serological status. Here, we report on the generation of a BVDV that expresses the EGFP reporter protein in addition to the viral proteins. Importantly, the recombinant virus replicated at reasonably high levels and remained genetically stable through at least five passages. Using the EGFP-expressing BVDV as a technical basis, a flow cytometry (FC)-based virus neutralization test (VNT) was established. This assay was quantitative and specific, and had highthroughput potential, which should enable effective screening of herds within days.
RESULTS

Generation and characterization of an EGFP-expressing BVDV
The first aim of this study was to establish a BVDV variant that expressed the easily detectable fluorescent reporter protein EGFP in addition to the viral proteins. The recombinant virus should replicate at high titres and display a genetic stability that would enable the production of large volumes of defined virus stocks. Following these outlines, we applied a previously established cDNA of the BVDV strain CP7 (BVDV-1 species) that was modified to a non-cytopathic biotype (NCP7) and that contained two unique restriction sites in the IS (NCP7SnaB/Pac; Fig. 1 ) (Baroth et al., 2010) . To generate the hybrid virus, a DNA fragment that consisted of the EGFP gene and a preceding encephalomyocarditis virus (EMCV) IRES was cloned into these sites. The resulting NCP7_EGFP cDNA accordingly encoded a bi-cistronic genomic viral RNA.
The viral proteins were expressed via the BVDV IRES, whilst EGFP was translated via the EMCV IRES ( Fig. 1 ).
Standard transfection/reinfection procedures with in vitro transcripts of the NCP7_EGFP cDNA were next performed. Thus, at 72 h post-transfection (p.t.) of MDBK (Madin-Darby bovine kidney) cells with the RNA, we detected EGFP synthesis in~5-10 % of the cells by fluorescence microscopy. Immunofluorescence staining of the BVDV NS3 protein, which was detectable exclusively in the presence of viral RNA replication (Behrens et al., 1998) , revealed that~20 % of the cells were infected at 72 h p.t. (Fig. 2) . When the supernatant of the transfection experiment was passaged four times and cells were reinfected with the P4 supernatant,~80 % of the cells expressed EGFP and NS3 at 72 h post-infection (p.i.) (Fig. 2) . These data demonstrated that the recombinant bi-cistronic viral RNA replicated in the transfected cells and that infectious virus particles were generated (in the following designated BVDV NCP7_EGFP). Most importantly, viral replication and infection were each detectable via EGFP synthesis.
Next, we evaluated the stability and growth characteristics of the EGFP-expressing hybrid virus. Addressing the first issue, BVDV NCP7_EGFP was grown side-by-side with the parental virus BVDV NCP7SnaB/Pac for nine passages. At each reinfection step, the total RNA of the culture supernatants was extracted and subjected to reverse transcription (RT)-PCR with primers binding upstream and downstream of the EGFP-encoding insert. As shown in Fig. 3(a) , the RT-PCR of RNA species that derived from infections with BVDV NCP7_EGFP yielded essentially one predominant PCR product up to passage P7. This had the expected size of 1500 versus~170 bp that was amplified from the 39 NTR of BVDV NCP7SnaB/Pac (i.e. in the absence of an insert). This indicated that the EMCV IRES-EGFP insert remained stable in the BVDV 39 NTR for at least six passages. At P7, The variable (39 V) and conserved (39 C) regions (see text) are indicated; an arrow marks the proposed boundary between both regions (Deng & Brock, 1993) . The structures of SLI, SLII and SLIII (also termed SL stop ) were verified experimentally (Yu et al., 1999; Isken et al., 2004) . The IS contains the SnaBI and PacI restriction sites (underlined sequences) and the EMCV IRES-EGFP insert. Note that the RNA may be folded differently with the inserted EMCV IRES-EGFP insert. The sequence of the EMCV IRES-EGFP insert is supplied in Fig. S1 (available in the online Supplementary Material).
additional, smaller RT-PCR products were detectable, the relative amounts of which increased strongly during P8 and P9 ( Fig. 3a ). We interpreted this finding such that during the last series of passages, BVDV variants with smaller versions of the NCP7_EGFP genome emerged that lacked major portions of the insert. Apparently, these species had a growth advantage in comparison with the intact recombinant virus, which explained the abrupt fading of the intact NCP7_EGFP RNA during one passage (see Discussion). To finally determine the genetic stability of the NCP7_EGFP genome, we sequenced the PCR products that were obtained by RT-PCR from P5 supernatants. Importantly, with PCR products that were raised in three independent transfection/reinfection procedures, the sequences of the BVDV NCP7_EGFP 39 NTR and of the EMCV IRES-EGFP insert were found to be essentially unchanged in comparison with those of the parental constructs ( Fig. S1 ). This confirmed that BVDV NCP7_EGFP remained unchanged through at least five passages.
Finally, we compared the growth characteristics of BVDV NCP7_EGFP with those of BVDV NCP7SnaB/Pac. For this, both variants were grown to P5 and the virus titres measured by end-point dilution. Whilst BVDV NCP7SnaB/Pac was confirmed to grow to titres that ranged between 10 7 and 10 8 TCID 50 ml 21 (Baroth et al., 2010) , BVDV NCP7_EGFP achieved peak titres between 10 6 and 10 7 TCID 50 ml 21 (Fig. 3b ). Subsequently, we applied the P5 supernatants of both variants to infect MDBK cells at m.o.i. 1 and performed one-step growth curves side-by-side for 72 h (standard protocol). BVDV NCP7_EGFP was found to replicate at a slightly lower rate than the parental virus ( Fig. 3b ).
Taken together, these data revealed that the replication competence of BVDV NCP7_EGFP is slightly hindered by the additional genetic unit within the 39 NTR. Despite this obstacle, the BVDV NCP7_EGFP viral RNA remains stable up to P6, which enabled the reproducible generation of P4 or P5 culture supernatants that contained recombinant virus at defined titres (see Discussion).
FC-based VNT
To apply BVDV NCP7_EGFP in a VNT (see scheme in Fig.  4a ), it was first important to define effective and reproducible infection and detection parameters. For this, we generated a set of P5 virus stocks by several independent transfection/ passaging procedures. At P5, we obtained a maximum number of infected cells (Fig. S2a ); the titres of these stocks were determined to be~2610 6 TCID 50 ml 21 (not shown).
The stocks were then applied in a series of experiments aimed at optimizing the infection and cultivation conditions to obtain reproducible numbers of infected cells (data not shown; details supplied on request). Thus, independent of the applied stock, infections of 60-70 % confluent MDBK cells at m.o.i. 1, a time of infection (i.e. exposure to virus) of the cells of 2 h and a subsequent cultivation period of 48 h p.i. turned out to be optimal. These conditions yielded a highly reproducible number of infected cells (20-30 %) that were detectable by FC via EGFP expression ( Figs S2b and 4a ). The relatively small infection rate was related to the replication efficiency of BVDV NCP7_EGFP (Fig. 3b ) and not to the FC detection system. This was confirmed when we tested BVDV NCP7_EGFP side-by-side with the BVDV NCP7 parent. For this, we applied the above-described conditions and evaluated the infection by FC as well as microscopy via immunofluorescence staining of NS3. With both FC and microscopy, . The cells were fixed, and the nuclei stained and visualized by DAPI staining. The viral protein NS3 was visualized by indirect immunofluorescence using a Cy3-labelled secondary antibody (see Supplementary Methods) . Alternatively, the synthesized EGFP was visualized. The applied wavelength ranges (excitation/emission) and exposure times are indicated.
the infection rate was found to be constantly higher with the parent virus (50-70 % of the cells; not shown).
Pilot VNTs with BVDV NCP7_EGFP were performed with a mAb directed against the BVDV structural envelope protein E2, which is an essential determinant of the viral infection process (Wang et al., 2004; El Omari et al., 2013) . A dose (see Methods) of this mAb that caused 100 % neutralization of the applied virus sample was established and accordingly used as a positive control in the VNT (Fig. 4b) . In a second approach, we tested the sera of three cattle: one animal (no. 412) that had no contact with BVDV ('non-infected'), one (no. 417) that was vaccinated (Pregsure BVD/Vacoviron; Frey et al., 2002) and one (no. 51) that was naturally infected ('field-virus-infected'). When applied at 10-fold dilution steps, we observed evident differences in the degree of neutralization mediated by the three different sera (Fig. 4c) . The difference between antibody-positive and -negative sera was most obvious when these were applied at 1 : 100 dilution (Fig. 4b, c ). The serum of the vaccinated animal caused the highest degree of neutralization (~99 %), whilst that of the field-virus-infected animal neutralized 70 % of the virus infectivity. Neutralization was ,15 % with the serum of the non-infected animal.
Next, we repeated the VNT using BVDV NCP7_EGFP, the anti-E2 mAb and the different sera (at a fixed dilution of 1 : 100), and counted the infected (EGFP-expressing) cells by microscopy or FC. In a comparison of the mean values of detected fluorescent cells and calculated virus neutralization, S2b ). With anti-E2 mAb-treated BVDV NCP7_EGFP, the EGFP-synthesizing cells were in the range of ,1 %. (b) VNT performed with cattle sera at one dilution ('short-cut' procedure). The VNT was performed at the optimized conditions. The anti-E2 mAb was applied both types of analysis yielded highly congruent results (Table  1 ). These data indicate that the FC analysis of the VNT was as reliable as the analysis by microscopy.
To further evaluate the newly established FC-based VNT, it was next used to define the antibody titres (log ND 50 values, i.e. log of serum dilution, where 50 % of the tested samples showed a complete neutralization of BVDV NCP7_ EGFP) of five sera of vaccinated cattle, five sera of field-virusinfected cattle and five sera of non-infected cattle. For this purpose, the sera were end-point titrated at threefold dilution steps and incubated with a defined volume of a BVDV NCP7_EGFP P5 stock. As shown in Table 2 , the values obtained correlated closely with the values that were measured with the same sera in a different laboratory that used a certified VNT (cVNT; Diagnostic Laboratory, Institute of Virology, Giessen, Germany). The cVNT applied BVDV-1 strain Osloss for neutralization; infected cells were detected microscopically by immunofluorescence staining of NS3. Both VNTs revealed that all vaccinated and field-virus-infected animals had developed detectable titres of BVDV-neutralizing antibodies.
DISCUSSION
A recombinant bi-cistronic BVDV, BVDV NCP7_EGFP, was constructed that encodes a second IRES and the coding region of the EGFP reporter in addition to the viral ORF. The expression of EGFP enables the straightforward detection of replicating virus in infected cells by either microscopy or FC and both procedures yield equivalent results (Table 1) . The generation of this recombinant virus was enabled by earlier work that defined a site (IS) within the 39 V region of the BVDV NCP7 39 NTR to be suitable for the stable introduction of foreign RNA elements (Baroth et al., 2010) ( Fig. 1) . However, in contrast to our earlier BVDV constructs and those of others (Fan et al., 2008) , BVDV NCP7_EGFP contains a whole additional translational unit. Importantly, this insert remained stably integrated within the viral RNA (i.e. without any nucleotide exchanges) through many replication cycles (Figs 3a and S1 ).
The 39 NTR was demonstrated previously to be an important regulatory element of the viral life cycle. The SLIII (also termed SL stop ) element is involved in the effective termination of translation of the BVDV ORF (Isken et al., 2004) ; the SLII, SS and SLI RNA elements are essential for the initiation of RNA replication (Yu et al., 1999) (Fig. 1) . In this respect, it is remarkable that the presence of a whole additional gene within the IS still enabled the authentic synthesis of the viral proteins and the formation of a functional viral replication complex. We interpret this finding such that the folding of each of the different functional elements of the 39 NTR (Fig.  1) is not substantially compromised by the insertion and that also the flanking viral sequence elements do not interfere with EMCV IRES-mediated translation of the EGFP-coding unit.
as a positive control. The indicated sera were applied at 1 : 100 dilution, which showed the most evident differences between antibody-positive and -negative sera [see (c)]. The cells were analysed by FC, the data evaluated by CellQuest Pro and the degree of neutralization determined (see Methods). Error bars represent SD of three independent experiments. (c) VNT performed with cattle sera at different dilutions. BVDV NCP7_EGFP P5 supernatants of defined titres were pre-treated with the different sera at the indicated dilution and used for infection and FC analysis as described in (a) and (b). Error bars represent SD of three independent experiments. The mean values obtained by FC and microscopy were compared for significant differences using Student's t-test (a50,01; a/250.005). The t-test indicated that no differences existed between the values determined by FC and microscopy (confidence level 99 %; data not shown).
However, BVDV NCP7_EGFP has a replication defect. This was indicated by a slightly lower growth rate compared with the parent strain and because the insert was finally lost at passage P8. The latter phenomenon was explained by RNA recombination events (Nagy et al., 1999; Kim & Kao, 2001; Austermann-Busch & Becher, 2012 ) that enabled the emergence and selection of fast replicating quasispecies that lacked the entire insert or parts of it (Fig. 3) . Nevertheless, our data indicate the frequency of such recombination events to be low. In fact, through several independent transfection/passaging experiments (n55), BVDV NCP7_ EGFP remained stable up to P6 (some data not shown).
The results suggest that the IS may also be used for the insertion of other heterologous coding units into the BVDV genome.
The remarkable stability of BVDV NCP7_EGFP permits a steady regeneration of the recombinant virus. This was confirmed during the independent preparation of several P5 stocks. As outlined, BVDV NCP7_EGFP remained stable in all cases and the stocks showed comparable titres. Moreover, these experiments revealed that frozen virus stocks could be stored for months (loss of titre per freezethaw cycle~0.5 log), and that it is possible to generate P4 and P5 supernatants at litre volumes (not shown). BVDV NCP7_EGFP was thus indicated to be applicable for highthroughput screening procedures (see below).
Similar to a previous approach with vaccinia virus (Cosma et al., 2004) , the EGFP-expressing BVDV was applied to an EGFP-based VNT. For this, a series of procedures had to be newly established. Measures were defined that enabled the adherent MDBK cells to be used in the FC (see Methods), and the neutralization and infection conditions as well as the cultivation period of the infected cells were standardized. These optimization studies were performed with different, independently raised BVDV NCP7_EGFP stocks, an efficiently neutralizing anti-E2 mAb and three types of cattle antisera. The antisera derived from vaccinated, fieldvirus-infected and non-infected animals, and accordingly represented the different conceivable infection situations of cattle herds. The field virus sera came from a random collection of BVDV-1-infected animals where the viral genetic subtypes were unknown. A 'short-cut' VNT that applied the optimized conditions and one serum dilution had already revealed substantial differences between the different sera (Fig. 4) . The data were further strengthened when we tested the sera end-point diluted in the VNT and when antibody titres were determined (Table 2) . Vaccinated animals clearly had the highest titres of neutralizing antibodies that mediated a nearly 100 % neutralization of BVDV NCP7_EGFP, even at high dilutions. In contrast, the results with the field-virus-infected animals varied considerably and thus reflected the natural spectrum of reactions to BVDV infections: whilst four animals had significant titres, one serum showed a low titre. Most importantly, the log ND 50 values that were obtained with the FC-based VNT correlated closely with the values that were obtained with an immunofluorescence and microscopy-based VNT (Table 2) . These findings corroborate the reliability of the FC-based VNT and support the opinion that the assay is competitive. As outlined, the main objectives of BVDV control programmes are the detection (and elimination) of PI animals, enhanced immunity through vaccination and biosecurity. Along these lines, a crucial subject concerns the screening for the presence of anti-BVDV antibodies. This is important during the development and validation of vaccination approaches, and, in the field, to determine if non-vaccinated herds or individual animals have come in contact with virus (e.g. by Trojan PI animals). In the future, with an expansion of eradication programmes (Ridpath, 2012; Ståhl & Alenius, 2012) , the number of BVDV-negative herds is expected to increase, whilst the number of vaccinated animals will decrease. Accordingly, routine controls of whole herds for the presence of antibodies in sera or milk (Niskanen, 1993) will be essential to trace outbreaks immediately.
All diagnostic assays face the challenge that they should enable an effective screen of cattle herds and free-ranging ruminants for infections by most, if not all, BVDV species and subtypes. ELISAs that simply measure the absence or presence of antibodies are fast and relatively easy to perform. However, ELISAs have technical downsides as they detect the target indirectly and semiquantitatively, which may reveal false positives and may require repeated testing (Houe et al., 2006) . VNTs quantify the biologically most relevant virus-neutralizing antibodies, and, accordingly, yield accurate and specific data. However, many neutralizing antibodies are directed against the E2 protein, which shows a high degree of antigenic diversity. VNT-detected antibody titres may thus vary if a certain serum is tested against different challenge viruses (Couvreur et al., 2002; Sandvik, 2005) .
To address this issue, we compared two VNTs that were performed in different laboratories, and that applied different methodologies and different BVDV-1 strains (NCP7 and Osloss). The fact that both tests yield congruent results (Table  2) is therefore relevant for a second reason as it reveals a high reproducibility of data between different laboratories, which is a problem with the VNTs in current use (Dubovi, 2013) . Moreover, the newly developed FC-based VNT was shown to share important technical characteristics with the certified control cVNT. The cVNT applied here reveals only minimal differences in titres of animals that were infected with one BVDV species and it also detects BVDV-2-infected animals (Avalos-Ramirez et al., 2001; M. König, unpublished data) . This remarkable 'species independence' may relate to two or three strongly neutralizing epitopes in the E2 protein which display an antigenic structure that is conserved between CSFV, BVDV-1 and BVDV-2 (reviewed by van Rijn, 2007; Dubovi, 2013; Ridpath, 2013) . In conclusion, a comprehensive validation of the BVDV NCP7_EGFP-based VNT requires further tests that should involve a broad spectrum of samples of animals infected with different BVDV-1 and BVDV-2 subtypes.
Should the FC-based VNT turn out to be unsuitable for the detection of BVDV-2 infections, a similarly constructed EGFP-expressing BVDV-2 recombinant may be included as a second challenge virus in the assay. For this, recently recovered BVDV-2 infectious cDNAs (e.g., see Meyer et al., 2002; Mischkale et al., 2010 ) may be applied. A constellation with two reporter-containing viral RNAs may allow us to discriminate between BVDV-1 and BVDV-2 infections during routine screens. This would be an important advantage over the available diagnostic tests that do not have this option.
Conventional VNTs such as the applied control cVNT are labour intensive and require 4-5 days to perform. The new FC-based VNT only takes 48 h, i.e. essentially the time required to establish and detect a BVDV infection in cell culture (Fig. 4) . Considering that the end-point dilution procedure may be automated fully (Black et al., 2011) and that the test is easily adaptable to high-number-well plates (e.g. 384) to be analysed by high-throughput FC, the sera of whole herds may be screened within this time. The potential of the FC-based VNT may be further exploited by establishing an optimized ('short-cut') one-dilution procedure (Fig. 4) . Other advantages of the test are that it is precise due to the direct and automated counting of infected cells, and that it requires only little manpower. An automated VNT is accordingly expected to further limit variations between different laboratories and to compensate for the less advantageous cost-time relationship of VNTs in comparison with ELISA.
In organized disease control programmes, a high-throughput FC-based VNT may enable a quick, cost-effective check of cattle herds in vaccination programmes, i.e. to test for a protective immune response shortly after immunization and to evaluate the serological status of each individual in the long term. A high-throughput VNT may also be applicable as a first screen of animals of non-vaccinated herds that are .6-9 months of age (i.e. without colostral antibodies) for seropositives. If the VNT turns out positive for at least one animal, a second test for the presence of virus will be required (e.g. by RT-PCR), specifically to identify PI animals. Hence, during eradication programmes, an effective VNT may reduce considerably the need for time-consuming, labour-intensive and expensive RT-PCR testing (see supplementary material for further aspects of Discussion). NCP7 ORF and the 39 NTR, respectively. PCR products that were generated from the viral RNA of P5 supernatants were sequenced directly by Eurofins MWG Operon using the same set of primers.
METHODS
Analysis of infection experiments by FC.
A FACSCalibur (Becton Dickinson) was used for the FC analysis. For a direct analysis of MDBK cells that were infected with BVDV NCP7_EGFP, between 3610 5 and 3610 6 cells were harvested with TrypLE Express solution (Gibco), washed once with PBS and resuspended in 1 ml PBS. Cells (10 5 ) were analysed and the percentage of infected cells determined by measuring EGFP fluorescence (see below).
VNT. The FC-based VNT was established in this study. Titrated BVDV NCP7_EGFP virus supernatants were applied at a defined volume of virus stock that contained the same number of p.f.u. as cells that were later infected (m.o.i. 1). The virus supernatant was used either untreated (negative control), treated with a mAb (positive control) or treated with the sera to be analysed [15 min in supplemented Dulbecco's modified Eagle medium (DMEM) (DMEM + ; Gibco; supplemented with 5 % (v/v) fetal calf serum, 100U/ml Penicillin (Gibco), 100 mg/ml Streptomycin (Gibco), 0.25 mg/ml Hypoxanthin (Sigma-Aldrich) and 0.1 mg/ml d-Biotin (Sigma-Aldrich)) at 20 uC].
The mouse anti-E2 IgG1 mAb WB214 (anti-E2 mAb) was used at 1 : 100 dilution of the material supplied by the manufacturer (Veterinary Laboratories Agency). To determine the antibody titre (log ND 50 ), the sera were end-point titrated at threefold dilution steps. Following the pre-incubation period, the virus/antibody mixtures were added to 60-70 % confluent MDBK cells in 96-well plates (~2610 4 cells per well) and the infection performed for 2 h. After cultivation for 48 h, 5000 cells were analysed by FC (see above). The percentage of BVDV NCP7_EGFP-infected MDBK cells was monitored via EGFP fluorescence using CellQuest Pro software (Becton Dickinson). The degree of neutralization was determined as (Cosma et al., 2004) : [12(EGFPexpressing cells after infection with serum or antibody-treated virus/ EGFP-expressing cells after infection with untreated virus)]6100 %.
Serum samples and characterization of neutralizing antibodies. Serum samples were obtained from the diagnostic laboratory of the Institute of Virology (Giessen). The samples comprised sera from vaccination studies prior to immunization (non-infected nos 412, 414, 415, 416, 427) , after single-dose vaccination (vaccinated no. 233) or after booster vaccination (vaccinated nos 416 (2), 417, 428, 429) with commercial vaccines against BVDV. Five sera were field samples (field-virus-infected nos 37, 45, 51, 66, 75) with no additional data available. All blood samples were heat-treated for 30 min at 56 uC to inactivate complement. Neutralizing antibodies against BVDV-1 were measured in a routine assay using 100 TCID 50 BVDV-1b strain Osloss on MDBK cells. Results were read by indirect immunofluorescence after 72 h and log ND 50 values calculated.
Statistics. The mean values obtained by microscopy and FC were compared for significant differences using Student's t-test.
